Atrial Natriuretic Peptide Ameloriates Diabetic Cardiomyopathy in Insulin-Deficient Rats in Vivo
R. Ritchie,A. Cao,H. Kiriazis,Q. Xu,X. -J. Du,D. M. Kaye
DOI: https://doi.org/10.1016/j.yjmcc.2006.06.051
IF: 5.763
2006-01-01
Journal of Molecular and Cellular Cardiology
Abstract:Diabetic cardiomyopathy is characterised by abnormalities in diastolic function, cardiac hypertrophy and fibrosis. We have demonstrated that diabetic cardiomyopathy in diabetic rats is associated with NADPH oxidase upregulation. The antihypertrophic actions of atrial natriuretic peptide (ANP) in vitro are mediated at least in part by NADPH oxidase suppression. Our objective was to test the hypothesis that ANP limits the functional and structural components of diabetic cardiomyopathy in type 1 diabetes, and elucidate whether antioxidant actions contribute to this protection. ANP treatment (10 pmol/kg/min sc, n=13) over the last 4 weeks of eight weeks streptozotocin diabetes significantly improved left ventricular (LV) diastolic dysfunction, by 22±6% on early/late diastolic filling (echocardiography-derived E/A ratio, P<0.05 vs untreated STZ) and tended to improve LVdP/dtmin by 15±9% (cardiac catheterization, p=0.1). Aortic flow velocity and velocity of circumferential fibre shortening were also improved by ANP, by 19±7% (P<0.05) and 14±6% (P=0.07). No changes in LV systolic pressure or LVdP/dtmax were observed. ANP significantly and potently attenuated LV expression of the hypertrophic gene β-myosin heavy chain (by 69±5%, p<0.001) and of NADPH oxidase (by 79±7%, p<0.05). Aortic NADPH-driven superoxide generation was also decreased by ANP, by 69±5% (P<0.01). Both the ACE inhibitor ramipril (1 mg/kg/day, n=12) and the antioxidant tempol (1.5 mmol/kg/day sc, n=11) improved diastolic, but not systolic, function. Tempol was the only treatment that attenuated cardiac fibrosis. In conclusion, our results demonstrate that ANP ameliorates diabetes-induced disturbances in myocardial function. These studies may lead to new therapies, based on natriuretic peptide and/or antioxidant approaches, for diabetic cardiomyopathy.
What problem does this paper attempt to address?